RATIONALE: Phenotypic distinctions between severe asthma (SA) and nonsevere asthma (NONSA) may be confounded by differential adherence or incorrect use of corticosteroids. OBJECTIVES: To determine if there are persistent phenotypic distinctions between SA (as defined by 2014 American Thoracic Society/European Respiratory Society guidelines) and NONSA after intramuscular triamcinolone acetonide (TA), and to identify predictors of a corticosteroid response in these populations. METHODS: A total of 526 adults age 18 years and older (315 SA) and 188 children age 6 to less than 18 years (107 SA) in the NHLBI Severe Asthma Research Program III were characterized before and 3 weeks after TA. The primary outcome for corticosteroid response was defined as greater than or equal to 10-point improvement in percent predicted FEV1. MEASUREMENTS AND MAIN RESULTS: Adult asthma groups exhibited a small but significant mean FEV1% predicted improvement after TA (SA group mean difference, 3.4%; 95% confidence interval, 2.2-4.7%; P = 0.001), whereas children did not. Adult SA continued to manifest lower FEV1 and worse asthma control as compared with NONSA after TA. In children, after TA only prebronchodilator FEV1 distinguished SA from NONSA. A total of 21% of adults with SA and 20% of children with SA achieved greater than or equal to 10% improvement after TA. Baseline bronchodilator response and fractional exhaled nitric oxide had good sensitivity and specificity for predicting response in all groups except children with NONSA. CONCLUSIONS: One in five patients with SA exhibit greater than or equal to 10% improvement in FEV1 with parenteral corticosteroid. Those likely to respond had greater bronchodilator responsiveness and fractional exhaled nitric oxide levels. In adults, differences in airflow obstruction and symptoms between SA and NONSA persist after parenteral corticosteroids, suggesting a component of corticosteroid nonresponsive pathobiology in adults with SA that may differ in children. Clinical trial registered with www.clinicaltrials.gov (NCT 01606826).
RATIONALE: Phenotypic distinctions between severe asthma (SA) and nonsevere asthma (NONSA) may be confounded by differential adherence or incorrect use of corticosteroids. OBJECTIVES: To determine if there are persistent phenotypic distinctions between SA (as defined by 2014 American Thoracic Society/European Respiratory Society guidelines) and NONSA after intramuscular triamcinolone acetonide (TA), and to identify predictors of a corticosteroid response in these populations. METHODS: A total of 526 adults age 18 years and older (315 SA) and 188 children age 6 to less than 18 years (107 SA) in the NHLBI Severe Asthma Research Program III were characterized before and 3 weeks after TA. The primary outcome for corticosteroid response was defined as greater than or equal to 10-point improvement in percent predicted FEV1. MEASUREMENTS AND MAIN RESULTS: Adult asthma groups exhibited a small but significant mean FEV1% predicted improvement after TA (SA group mean difference, 3.4%; 95% confidence interval, 2.2-4.7%; P = 0.001), whereas children did not. Adult SA continued to manifest lower FEV1 and worse asthma control as compared with NONSA after TA. In children, after TA only prebronchodilator FEV1 distinguished SA from NONSA. A total of 21% of adults with SA and 20% of children with SA achieved greater than or equal to 10% improvement after TA. Baseline bronchodilator response and fractional exhaled nitric oxide had good sensitivity and specificity for predicting response in all groups except children with NONSA. CONCLUSIONS: One in five patients with SA exhibit greater than or equal to 10% improvement in FEV1 with parenteral corticosteroid. Those likely to respond had greater bronchodilator responsiveness and fractional exhaled nitric oxide levels. In adults, differences in airflow obstruction and symptoms between SA and NONSA persist after parenteral corticosteroids, suggesting a component of corticosteroid nonresponsive pathobiology in adults with SA that may differ in children. Clinical trial registered with www.clinicaltrials.gov (NCT 01606826).
Entities:
Keywords:
corticosteroid response phenotype; pediatric and adult asthma; severe asthma
Authors: Nicolas Roche; Dirkje S Postma; Gene Colice; Anne Burden; Theresa W Guilbert; Elliot Israel; Richard J Martin; Willem M C van Aalderen; Jonathan Grigg; Elizabeth V Hillyer; Julie von Ziegenweidt; David B Price Journal: Am J Respir Crit Care Med Date: 2015-04-15 Impact factor: 21.405
Authors: Nicola A Hanania; Sally Wenzel; Karin Rosén; Hsin-Ju Hsieh; Sofia Mosesova; David F Choy; Preeti Lal; Joseph R Arron; Jeffrey M Harris; William Busse Journal: Am J Respir Crit Care Med Date: 2013-04-15 Impact factor: 21.405
Authors: Anneke ten Brinke; Aeilko H Zwinderman; Peter J Sterk; Klaus F Rabe; Elisabeth H Bel Journal: Am J Respir Crit Care Med Date: 2004-06-23 Impact factor: 21.405
Authors: Kian Fan Chung; Sally E Wenzel; Jan L Brozek; Andrew Bush; Mario Castro; Peter J Sterk; Ian M Adcock; Eric D Bateman; Elisabeth H Bel; Eugene R Bleecker; Louis-Philippe Boulet; Christopher Brightling; Pascal Chanez; Sven-Erik Dahlen; Ratko Djukanovic; Urs Frey; Mina Gaga; Peter Gibson; Qutayba Hamid; Nizar N Jajour; Thais Mauad; Ronald L Sorkness; W Gerald Teague Journal: Eur Respir J Date: 2013-12-12 Impact factor: 16.671
Authors: Paul E Moore; Jason T Poston; Debra Boyer; Emily Barsky; Jonathan Gaffin; Kathleen B Boyne; Kristie R Ross; Laura Beth Mann Dosier; Timothy J Vece; Alicia M Casey; Sebastian K Welsh; J Wells Logan; Edward G Shepherd; Pelton A Phinzy; Howard B Panitch; Christina M Papantonakis; Eric D Austin; Amir B Orandi; Maleewan Kitcharoensakkul; Mark K Abe; Amjad Horani; Jordan S Rettig; Jessica Pittman Journal: Ann Am Thorac Soc Date: 2017-08
Authors: Melody G Duvall; Cindy Barnig; Manuela Cernadas; Isabell Ricklefs; Nandini Krishnamoorthy; Nicole L Grossman; Nirav R Bhakta; John V Fahy; Eugene R Bleecker; Mario Castro; Serpil C Erzurum; Benjamin M Gaston; Nizar N Jarjour; David T Mauger; Sally E Wenzel; Suzy A Comhair; Andrea M Coverstone; Merritt L Fajt; Annette T Hastie; Mats W Johansson; Michael C Peters; Brenda R Phillips; Elliot Israel; Bruce D Levy Journal: Sci Immunol Date: 2017-03-10
Authors: Anne M Fitzpatrick; Stanley J Szefler; David T Mauger; Brenda R Phillips; Loren C Denlinger; Wendy C Moore; Ronald L Sorkness; Sally E Wenzel; Peter J Gergen; Eugene R Bleecker; Mario Castro; Serpil C Erzurum; John V Fahy; Benjamin M Gaston; Elliot Israel; Bruce D Levy; Deborah A Meyers; W Gerald Teague; Leonard B Bacharier; Ngoc P Ly; Wanda Phipatanakul; Kristie R Ross; Joe Zein; Nizar N Jarjour Journal: J Allergy Clin Immunol Date: 2019-10-08 Impact factor: 10.793
Authors: Annette T Hastie; David T Mauger; Loren C Denlinger; Andrea Coverstone; Mario Castro; Serpil Erzurum; Nijar Jarjour; Bruce D Levy; Deborah A Meyers; Wendy C Moore; Brenda Phillips; Sally E Wenzel; John V Fahy; Elliot Israel; Eugene R Bleecker Journal: J Allergy Clin Immunol Date: 2020-02-05 Impact factor: 10.793
Authors: Michael C Peters; Sheena Kerr; Eleanor M Dunican; Prescott G Woodruff; Merritt L Fajt; Bruce D Levy; Elliot Israel; Brenda R Phillips; David T Mauger; Suzy A Comhair; Serpil C Erzurum; Mats W Johansson; Nizar N Jarjour; Andrea M Coverstone; Mario Castro; Annette T Hastie; Eugene R Bleecker; Sally E Wenzel; John V Fahy Journal: J Allergy Clin Immunol Date: 2018-03-07 Impact factor: 10.793
Authors: Isabell Ricklefs; Ioanna Barkas; Melody G Duvall; Manuela Cernadas; Nicole L Grossman; Elliot Israel; Eugene R Bleecker; Mario Castro; Serpil C Erzurum; John V Fahy; Benjamin M Gaston; Loren C Denlinger; David T Mauger; Sally E Wenzel; Suzy A Comhair; Andrea M Coverstone; Merritt L Fajt; Annette T Hastie; Mats W Johansson; Michael C Peters; Brenda R Phillips; Bruce D Levy Journal: JCI Insight Date: 2017-07-20